How Von Willebrand Factor Controls Blood Clotting

Von Willebrand factor (VWF) is a large, sticky glycoprotein in your blood whose main job is to grab onto platelets and anchor them at the site of a damaged blood vessel, forming the initial plug that stops bleeding. It also acts as a bodyguard for clotting factor VIII, shielding it from being broken down in the bloodstream. What makes VWF unusual among clotting proteins is that it does not simply float around waiting for an injury. It stays coiled up like a ball of yarn until fast-moving blood physically stretches it open, at which point it becomes active. That shear-dependent activation makes VWF uniquely important in arteries and small vessels where blood flow is rapid, and it explains why problems with VWF lead to a surprisingly wide range of diseases.

How VWF Is Made and Stored

VWF is produced in two types of cells: endothelial cells (the thin lining of every blood vessel) and megakaryocytes (the bone marrow cells that produce platelets). It starts as a large precursor molecule that first links into pairs in one part of the cell, then assembles into enormous chains called multimers in another compartment before being packaged for storage.¹ Endothelial cells store these multimers in cigar-shaped containers called Weibel-Palade bodies, while platelets carry them in alpha granules. When a vessel is injured or when signaling molecules trigger a release, these stores dump ultra-large VWF multimers into the blood or directly onto the vessel surface. The larger the multimer, the stickier it is, which matters when the body needs to plug a wound fast.

The Shear-Activation Trick

Most proteins in the clotting system are activated by enzymes. VWF is different: it is activated by the physical force of flowing blood. Under normal, calm flow, VWF stays curled into a compact globular shape. But when blood moves fast, particularly in narrowed or damaged arteries, the shear force pulls VWF apart like taffy. Researchers have shown that this unfolding is a sharp, reversible transition: below a critical shear rate the molecule stays balled up, and above it the molecule snaps into an elongated form.²

Once stretched, specific domains along the VWF chain become exposed. The A1 domain, in particular, stretches significantly under high shear and is the part that latches onto a receptor on platelets called glycoprotein Ibα.³ The beauty of this design is that it keeps VWF inert in slow-moving veins where clotting would be dangerous and activates it precisely in the high-flow environments where a wound needs immediate sealing. Computational modeling has further clarified that strong unfolding happens through two regimes: a tumbling motion near vessel walls in shear flow, and a more dramatic stretching in areas where flow has a strong extensional component, such as vessel branches or stenoses.⁴

Two Jobs at Once: Platelet Glue and Factor VIII Shield

VWF’s first and most visible job is catching platelets at the wound. When the inner layers of a blood vessel are exposed by injury, VWF binds to the exposed collagen through its A3 domain and simultaneously grabs passing platelets via its A1 domain. That initial grab happens at high speed and under drag forces that would rip most molecular bonds apart, yet the VWF-platelet interaction actually strengthens as the hydrodynamic drag increases.⁵ This counterintuitive behavior is a catch-bond phenomenon: the harder the blood tries to tear the platelet away, the tighter VWF holds on.

VWF’s second job is less dramatic but equally critical. It circulates bound to coagulation factor VIII (FVIII), the clotting protein that is deficient in hemophilia A. VWF’s D′D3 region cradles FVIII and protects it from being chewed up by enzymes or cleared too quickly by the liver. Without VWF, FVIII levels in the blood drop sharply, which is why people with severe VWF deficiency can bleed as though they have hemophilia.⁶ Early experiments showed that adding purified VWF to plasma from patients with von Willebrand disease could stabilize their FVIII levels, confirming this carrier relationship.⁷

The Built-In Brake: ADAMTS13

Ultra-large VWF multimers are excellent at plugging wounds, but if they persist in the circulation they can also trigger unwanted clots. The body controls this with ADAMTS13, a metalloprotease that is always active in the blood. ADAMTS13 works by cutting a single bond in VWF’s A2 domain, trimming the giant multimers down to safer sizes.⁸ The clever part is that the A2 domain is buried when VWF is in its compact, globular shape. ADAMTS13 can only reach the cutting site when shear forces stretch VWF open and expose it.⁹ So the same mechanical event that activates VWF for platelet binding also sets the timer for its own destruction. The result is a self-limiting system: VWF unfolds, catches platelets, and gets trimmed before it can accumulate into dangerous masses.

When VWF Is Too Low: Von Willebrand Disease

Von Willebrand disease (VWD) is the most common inherited bleeding disorder, caused by having too little VWF or VWF that does not work properly.¹⁰ It was first identified in 1924 by Finnish physician Erik Adolf von Willebrand, who studied a family on the Åland Islands suffering from a bleeding disorder distinct from hemophilia.¹¹

VWD is classified into types based on whether the problem is the amount of VWF or its quality:¹²

Type 1: Partial reduction in VWF levels. The most common form, usually mild.
Type 3: Near-complete absence of VWF. Rare but severe, with significant bleeding and very low FVIII levels.
Type 2A: VWF is present but missing the large multimers that are best at catching platelets.
Type 2B: VWF has abnormally increased affinity for platelets, which paradoxically causes bleeding because it gets cleared from circulation too fast.
Type 2M: VWF binds poorly to platelets even though large multimers are present.
Type 2N: VWF cannot bind factor VIII properly, mimicking hemophilia A.

Among the type 2 subtypes, bleeding severity varies considerably. In a large cohort of over 370 genetically confirmed type 2 patients, those with type 2A had the highest bleeding scores (median of 7 on a standardized scale), followed by type 2B and then types 2M and 2N. But even individuals carrying the exact same genetic variant could differ widely in how much they bled, suggesting that other genes, lifestyle, and hormonal factors modify the clinical picture.¹³

When VWF Is Uncontrolled: Thrombotic Thrombocytopenic Purpura

If ADAMTS13 fails, the opposite problem emerges. Without that trimming enzyme, ultra-large VWF multimers accumulate and form platelet-rich microclots in tiny blood vessels throughout the body, a condition called thrombotic thrombocytopenic purpura (TTP). Those clots chew through red blood cells (causing anemia), consume platelets (causing easy bruising and bleeding), and block blood flow to organs like the brain and kidneys.¹⁴ TTP is life-threatening without treatment.

ADAMTS13 activity below roughly 10% of normal is the threshold that tips the balance toward TTP. This can happen through inherited mutations in the ADAMTS13 gene or, more commonly in adults, through autoimmune antibodies that block the enzyme.¹⁵ The autoimmune form accounts for most adult cases and is treated with plasma exchange to remove the antibodies and replenish ADAMTS13.¹⁶

Blood Type and VWF Levels

One of the more surprising things about VWF is that your ABO blood type meaningfully affects how much of it circulates in your plasma. People with blood type O have roughly 25% lower VWF levels than people with types A, B, or AB.¹⁷ The reason does not appear to be a difference in how much VWF the body makes. Instead, VWF is cleared from the blood much faster in type O individuals, with a half-life of about 10 hours compared with roughly 25 hours in non-O individuals.¹⁸

The mechanism appears to involve the carbohydrate structures that decorate VWF. ABO blood group antigens are sugar molecules, and VWF carries these sugars on its surface. People with blood type O have more H antigen on their VWF, and higher H antigen levels correlate with lower VWF plasma concentrations, suggesting that the type of sugar coating influences how quickly the body clears VWF from circulation.¹⁹ This has practical consequences: blood type O individuals are overrepresented among people diagnosed with type 1 VWD, sometimes making it tricky to distinguish a genuinely abnormal VWF level from the lower end of normal for that blood type.

VWF and Stroke Risk

Because VWF promotes clotting, chronically elevated levels are not benign. Elevated VWF has been linked to increased risk of arterial thrombotic events. In a case-control study of ischemic stroke, people with VWF antigen levels in the highest quarter of the distribution had roughly three times the odds of having a stroke compared to those in the lowest quarter.²⁰ VWF levels tend to rise with age, inflammation, and endothelial damage, all of which are also cardiovascular risk factors. Whether VWF is a direct cause of thrombosis in these settings or mainly a marker of underlying vascular injury remains an active area of research, though the mechanistic picture of VWF directly recruiting platelets into arterial thrombi makes a causal role plausible.

Beyond Clotting: VWF in Inflammation

For decades VWF was considered a purely hemostatic protein. That view has shifted. Research now shows that VWF participates in vascular inflammation through several mechanisms, including helping white blood cells cross blood vessel walls, modulating vascular permeability, and interacting with the complement immune system.²¹

In animal models of inflammation, blocking VWF with antibodies reduced neutrophil recruitment into inflamed tissue by about half.²² The pathway turns out to involve platelets: VWF sticks to the vessel wall and catches circulating platelets, and those captured platelets then help neutrophils squeeze through the endothelium. Blocking the VWF A1 domain with a targeted nanobody could resolve both leukocyte recruitment and vascular leakage in inflammation models, pointing toward VWF as a potential therapeutic target in inflammatory diseases, not just bleeding or clotting disorders.²³

Acquired VWF Problems from Mechanical Devices

VWF’s sensitivity to shear forces creates an unusual clinical problem for people with left ventricular assist devices (LVADs), the mechanical pumps implanted in patients with advanced heart failure. The high shear environment inside an LVAD stretches VWF continuously, allowing ADAMTS13 to chop up the large multimers much faster than normal. The result is a loss of the most hemostatically active VWF forms and reduced ability to bind platelets and collagen, a condition called acquired von Willebrand syndrome. These changes develop rapidly after device implantation and reverse quickly once the device is removed, confirming that the abnormal flow pattern is the direct cause.²⁴ This complication means that LVAD patients often deal with a paradox: they are on blood thinners to prevent clots in the device, yet their VWF is simultaneously degraded, increasing their risk of mucosal bleeding.

Treatments That Target VWF

For people with von Willebrand disease, the first-line treatment in mild to moderate cases is desmopressin (DDAVP), a synthetic hormone that triggers endothelial cells to release their stored VWF. Because DDAVP works by mobilizing the body’s own reserves rather than providing an external product, it avoids the risks of blood-derived products. However, individual responses to DDAVP vary, so patients typically undergo a trial dose to see how much their VWF levels rise before it is relied on for surgeries or other high-bleeding-risk situations.²⁵ For severe VWD, or for patients who do not respond to DDAVP, replacement therapy with concentrates containing both VWF and FVIII is the standard approach.²⁶

VWF and Blood Vessel Formation

An emerging area of VWF research has nothing to do with clotting. In people who lack VWF entirely (type 3 VWD), a common complication is angiodysplasia, the formation of fragile, abnormal blood vessels in the gut that bleed repeatedly. This has long puzzled clinicians because these malformed vessels seem unrelated to VWF’s hemostatic role. Recent work suggests VWF plays a direct role in regulating how blood vessels grow and remodel. Endothelial cells that lack VWF show increased levels of angiopoietin-2, a molecule that destabilizes vessels. In VWF-deficient mice, gut blood vessels have elevated angiopoietin-2 and reduced support from the surrounding pericyte cells that normally reinforce vessel walls. When researchers blocked angiopoietin-2 in VWF-deficient cells, the abnormal sprouting and distorted vessel networks normalized, suggesting that angiopoietin-2 inhibitors could eventually help VWD patients who suffer from chronic gastrointestinal bleeding.²⁷

Why VWF Expression Differs Across Organs

Not all blood vessels produce VWF equally. In the brain, lungs, and liver of mice, VWF levels rise significantly with age, while the kidneys and heart show no such increase.²⁸ This organ-specific pattern is controlled at the level of gene regulation. Specific repressor proteins silence the VWF gene in certain vascular beds: one repressor keeps it quiet in heart and lung endothelial cells, while a different one suppresses it in kidney vessels.²⁹ The age-dependent increases in some organs could help explain why older adults are more prone to stroke and other thrombotic events: their vessels may simply produce more of this potent platelet-recruiting protein over time.

An Ancient Molecule

VWF is not a recent evolutionary invention. A version of the VWF gene has been found in the hagfish, a jawless vertebrate whose lineage diverged from ours roughly 500 million years ago. The hagfish version is simpler, lacking the A3 domain that in mammals binds collagen under high-flow conditions, which suggests VWF acquired additional functional modules over evolutionary time.³⁰ Analysis of reconstructed ancestral VWF and FVIII proteins across mammals shows that the two molecules coevolved, maintaining tight binding to each other while independently tuning their hemostatic activities to suit different species.³¹ The conservation of VWF across such a vast evolutionary span underscores just how fundamental it is to vertebrate survival: an animal that cannot stop bleeding after an injury does not last long.

1
PubMed. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly ↩︎
2
PubMed Central. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers ↩︎
3
Journal of Molecular Liquids. Dynamic conformational response of von Willebrand factor to varying shear stress: A hybrid computational approach ↩︎
4
PubMed Central. A Continuum Model for the Unfolding of von Willebrand Factor ↩︎
5
Haematologica. Platelet interaction with von Willebrand factor is enhanced by shear-induced clustering of glycoprotein Ibα ↩︎
6
Blood. FVIII stabilization: VWF D′D3 will do ↩︎
7
PubMed Central. Stabilization of factor VIII in plasma by the von Willebrand factor ↩︎
8
PubMed Central. Proteolytic processing of von Willebrand factor by adamts13 and leukocyte proteases ↩︎
9
Blood. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor ↩︎
10
PubMed. Clinical diagnosis of von Willebrand disease ↩︎
11
PubMed. Diagnosing von Willebrand disease: a short history of laboratory milestones and innovations, plus current status, challenges, and solutions ↩︎
12
Thrombosis and Haemostasis. A Revised Classification of von Willebrand Disease ↩︎
13
PubMed Central. Genetic determinants of clinical variability in type 2 von Willebrand disease: bridging genotype and phenotype ↩︎
14
PubMed Central. Pathophysiology of thrombotic thrombocytopenic purpura ↩︎
15
PubMed Central. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura ↩︎
16
PubMed Central. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura ↩︎
17
PubMed Central. The relationship between ABO blood group, von Willebrand factor, and primary hemostasis ↩︎
18
Blood. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor ↩︎
19
PubMed. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels ↩︎
20
PubMed. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability ↩︎
21
PubMed Central. The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy ↩︎
22
Blood. von Willebrand factor promotes leukocyte extravasation ↩︎
23
PubMed. A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation-Brief Report ↩︎
24
PubMed Central. Acquired von Willebrand syndrome associated with left ventricular assist device ↩︎
25
PubMed Central. A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero? ↩︎
26
PubMed. Use of objective efficacy criteria for evaluation of von Willebrand factor/factor VIII concentrates ↩︎
27
bioRxiv. Von Willebrand Factor Deficiency Impairs Vascular Morphogenesis via Angiopoietin-2: Relevance for Gut Angiodysplasia ↩︎
28
PubMed. Aging Is Associated With Organ-Specific Alterations in the Level and Expression Pattern of von Willebrand Factor ↩︎
29
PubMed Central. Repressors NFI and NFY participate in organ-specific regulation of von Willebrand factor promoter activity in transgenic mice ↩︎
30
PubMed Central. Identification of extant vertebrate Myxine glutinosa VWF: evolutionary conservation of primary hemostasis ↩︎
31
PubMed Central. Molecular coevolution of coagulation factor VIII and von Willebrand factor ↩︎